Anticoagulants to prevent stroke occurrence and worsening

Israel Medical Association Journal

Volumn 8, Issue 11, 2006, Pages 773-778

  Caplan, Louis R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Arterial dissections; Cardiac embolism; Heparin; Large artery occlusions; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CILOSTAZOL; CLOPIDOGREL; DABIGATRAN; DANAPAROID; DIPYRIDAMOLE; FIBRIN; FIBRINOGEN; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROTHROMBIN; THROMBIN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; AORTA ATHEROSCLEROSIS; ARTERY DISSECTION; ARTICLE; BLEEDING; BLOOD CLOT; BLOOD CLOTTING; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; ERYTHROCYTE; FOOD; HEART ATRIUM FIBRILLATION; HEART ATRIUM SEPTUM DEFECT; HEART SURGERY; HUMAN; HYPERCOAGULABILITY; INDIVIDUALIZATION; INTERNATIONAL NORMALIZED RATIO; INTRACARDIAC THROMBOSIS; LIVER DISEASE; LUNG EMBOLISM; MEDICAL DECISION MAKING; OCCLUSIVE CEREBROVASCULAR DISEASE; PATIENT CARE; PATIENT MONITORING; RECURRENCE RISK; RISK BENEFIT ANALYSIS; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTE; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME;

ANTICOAGULANTS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HEPARIN; HUMANS; INTERNATIONAL NORMALIZED RATIO; THROMBOSIS; WARFARIN;

EID: 33751579406     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Caplan LR. Thrombosis and therapeutic antidotes. In: Bogousslavsky J, Hacke W, eds. Historical Aspects in Thrombolytic and Antithrombotic Therapy for Stroke. Abington, Oxon: Informa UK Ltd, 2006:1-11.
2. Kobayashi S, Tazaki Y. Effectiveness of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost 1997;23:531-4.
3. LaMonte MP, Nash ML, Wang DZ, et al., for the ARGIS-1 Investigators. Argabatran anticoagulation in patients with acute ischemic stroke (ARGIS-1). Stroke 2004;35:1677-82.
4. Caplan LR, Manning W. Brain Embolism. Boston: Decker, 2006 (in press)
5. Caplan LR. Stroke - A Clinical Approach. 3rd edn. Boston: Butterworth-Heinemann, 2000.
6. Halperin JL, for the Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146:431-8.
7. Olsson SB, for the Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1686-7
8. Albers GW, Diener HC, Frison L, et al., SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293(6):736-9.
9. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Stroke 1983;14:668-76.
10. Chamorro A, Vila N, Saiz A, Alday M, Tolosa E. Early anticoagulation after large cerebral embolic infarction. Neurology 1995;45: 861-5.
11. Chamorro A, Vila N, Ascaso C, Blanc R. Heparin in acute stroke with atrial fibrillation. Clinical relevance of early treatment. Arch Neurol 1999;56:1098-102.
12. Cerebral Embolism Task Force. Cardiogenic brain embolism. Arch Neurol 1986;43:71-84.
13. Cerebral Embolism Task Force. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch Neurol 1989;46:727-43.
14. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: brain hemorrhage and management options. Stroke 1984;15:779-89.
15. Furlan AJ, Cavalier S, Hobbs RE, Weinstein MA, Modic MT. Hemorrhage and anticoagulation after nonseptic embolic brain infarction. Neurology 1982;32:280-2.
16. Pessin MS, Estol C, Lafranchise F, Caplan LR. Safety of anti-coagulation after hemorrhagic infarction. Neurology 1993;43:1298-303.
17. Nater B, Bogousslavsky J, Regli F, Stauffer J-C. Stroke patterns with atrial septal aneurysms. Cerebrovasc Dis 1992;2:342-6.
18. Belkin RN, Hurwitz BJ, Kisslo J. Atrial septal aneurysm: association with cerebrovascular and peripheral embolic events. Stroke 1987;18:856-62.
19. Cabanes L, Mas JL, Cohen A, et al. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke 1993;24:1865-73.
20. Grosgogeat Y, Lhermitte F, Carpenter A, Facquet J, Alhomme P, Tran T. Aneurysme de la cloison interauriculaire revele par une embolie cerebrale. Arch Mal Coeur 1973;66:169-77.
21. Silver MD, Dorsey JS. Aneurysms of the septum primum in adults. Arch Pathol Lab Med 1978;102:62-5.
22. Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, Van Melle G. Stroke recurrence in patients with patent foramen ovale: the Lausanne study. Neurology 1996;46:1301-5.
23. The French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Recurrent cerebrovascular events in patients with patent foramen ovale or atrial septal aneurysms and cryptogenic stroke or TIA. Am Heart J 1995;130:1083-8.
24. Bridges ND, Hellensbrand W, Latson L, Filiano J, Newburger JW, Lock JE. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation 1982;86:2013-15.
25. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation 2002;105:2625-318.
26. Mohr JP, Thompson JLP, Lazar RM, et al., for the Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51.
27. Ameri A, Bousser M-G. Cerebral venous thrombosis. Neurol Clin 1992;10:87-111.
28. Jacewicz M, Plum F. Aseptic cerebral venous thrombosis. In: Einhaupl K, Kempkti O, Baethmann A, eds. Cerebral Sinus Thrombosis. Experimental and Clinical Aspects. New York: Plenum, 1990:157-70.
29. Einhaupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991;338:597-600.
30. Meister W, Einhaupl K, Villringer A, et al. Treatment of patients with cerebral sinus and vein thrombosis with heparin. In: Einhaupl K, Kempski O, Baethmann A, eds. Cerebral Sinus Thrombosis. Experimental and Clinical Aspects. New York: Plenum, 1990:225-30.
31. de Bruijn SFTM, Stam J, for the Cerebral Venous Sinus Thrombosis Study Group. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral venous sinus thrombosis. Stroke 1999;30:484-8.
32. Diaz JM, Schiffman JS, Urban ES. Superior sagittal sinus thrombosis and pulmonary embolism: a syndrome rediscovered. Acta Neurol Scand 1992;86:390-6.
33. Caplan LR. Worsening in ischemic stroke patients: is it time for a new strategy? Stroke 2002;33:1443-5.
34. International Stroke Trial Collaboration Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute stroke. Lancet 1997;349:1569-81.
35. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke. A randomized controlled trial. JAMA 1998;279: 1265-72.
36. Adams HP, Bendixen BH, Leira EC, et al. Antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999;53:122-5.
37. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305-16.
38. Koroshetz W. Warfarin, aspirin, and intracranial vascular disease. N Engl J Med 2005;352:1368-70.